new glp 1 agonist novo nordisk GLP-1 analogs, trend in obesity treatment, become even more effective < Pharma < Article Novo, Lilly Stocks Rise. Weight-Loss
Description
By 12 months, they had lost an average of 17.4% of their body weight
Bydureon: Summary of product characteristics
Blue Cross announced Thursday that starting on January 1, 2026, standard coverage plans will not cover GLP-1s for weight loss
GLP-1 medications slow gastric motility, which can affect bowel function
